GEP20247706B - Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis - Google Patents

Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Info

Publication number
GEP20247706B
GEP20247706B GEAP202116094A GEAP2021016094A GEP20247706B GE P20247706 B GEP20247706 B GE P20247706B GE AP202116094 A GEAP202116094 A GE AP202116094A GE AP2021016094 A GEAP2021016094 A GE AP2021016094A GE P20247706 B GEP20247706 B GE P20247706B
Authority
GE
Georgia
Prior art keywords
triiodothyronine
treatment
pharmaceutical composition
sepsis
hypoxemia
Prior art date
Application number
GEAP202116094A
Other languages
English (en)
Inventor
Iordanis Mourouzis
Constantinos Pantos
Original Assignee
Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A
Ioulia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A, Ioulia filed Critical Uni Pharma Kleon Tsetis Pharmasceutical Laboratories S A
Publication of GEP20247706B publication Critical patent/GEP20247706B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GEAP202116094A 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis GEP20247706B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης

Publications (1)

Publication Number Publication Date
GEP20247706B true GEP20247706B (en) 2024-12-10

Family

ID=76197481

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202116094A GEP20247706B (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
GEAP202416094A GEAP202416094A (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202416094A GEAP202416094A (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Country Status (13)

Country Link
US (1) US20230157982A1 (https=)
EP (1) EP4138810A1 (https=)
JP (1) JP2023538984A (https=)
KR (1) KR20230022839A (https=)
CN (1) CN115996710B (https=)
AU (1) AU2021258544A1 (https=)
BR (1) BR112022021250A2 (https=)
CA (1) CA3176106A1 (https=)
GE (2) GEP20247706B (https=)
IL (1) IL297398B1 (https=)
MX (1) MX2022013228A (https=)
WO (1) WO2021214497A1 (https=)
ZA (1) ZA202212502B (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1942995A (en) * 1994-03-15 1995-10-03 K.U. Leuven Research & Development New use of growth hormone
SI3908272T1 (sl) 2019-01-09 2023-07-31 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-trijodotironin (t3) za uporabo pri omejevanju mikrovaskularne obstrukcije

Also Published As

Publication number Publication date
JP2023538984A (ja) 2023-09-13
IL297398A (en) 2022-12-01
WO2021214497A1 (en) 2021-10-28
ZA202212502B (en) 2024-05-30
MX2022013228A (es) 2022-11-14
CA3176106A1 (en) 2021-10-28
AU2021258544A1 (en) 2022-10-27
IL297398B1 (en) 2026-01-01
BR112022021250A2 (pt) 2022-12-06
EP4138810A1 (en) 2023-03-01
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21
CN115996710B (zh) 2024-06-28
KR20230022839A (ko) 2023-02-16
US20230157982A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
CL2023000972A1 (es) Inhibidores de ras
CO2025015474A2 (es) Inhibidores macrocíclicos de ras
MX2020008271A (es) Inhibidor de fap.
CL2007001996A1 (es) Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes.
CO2020010303A2 (es) Conjugados de il-15, y sus usos
MX2022002633A (es) Mimeticos de hepcidina conjugada.
PH12023500004A1 (en) Conjugated hepcidin mimetics
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
GT200500260A (es) Amidas biciclicas como inhibidores de cinasa.
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
DOP2013000212A (es) Formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
MX2025012181A (es) Formas cristalinas de inhibidores de ras, composiciones que las contienen y metodos para su uso
NO20051539L (no) N-biarylmetylaminosykloalkankarboksamidderivater
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
EP1476419A4 (en) N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE
MX2021012359A (es) Inhibidores de la vía de señalización de notch y su uso en el tratamiento de cánceres.
MX2024012565A (es) Composiciones farmaceuticas de mosunetuzumab y metodos de uso
MX2024012582A (es) Composiciones farmaceuticas de proteinas terapeuticas y metodos de uso
CL2008003602A1 (es) Compuestos derivados de triazolotriazinas y triazolopirazinas sustituidas; composicion farmaceutica; y su uso en el tratamiento y/o profilaxis de trastornos hematologicos.
BRPI0513944A (pt) forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
GEAP202416094A (en) Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis
CL2023003237A1 (es) Inhibidores de la vía jak1 para el tratamiento del prurigo nodular